Laura Joszt is the Vice President of Content for a variety of healthcare publications, including Drug Topics, AJMC - The American Journal of Managed Care, and Managed Healthcare Executive. With a focus on healthcare policy, market trends, and new therapies, Laura's work has been featured in publications such as FormularyWatch and the Center for Biosimilars.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Laura's coverage heavily focuses on healthcare and pharmaceutical topics, particularly around reimbursement, biosimilars, pharmacy, and managed care. She frequently cites data in her articles which suggests she places a strong emphasis on evidence-based reporting.
Given her focus on specific aspects of the healthcare industry such as reimbursement and biosimilars, she would likely be interested in sources with expertise or direct involvement in these areas. Pitches offering insights into evolving trends within the healthcare landscape or new research findings may also resonate well with Laura.
Since there is no specified geographic focus for Laura Joszt’s coverage, it can be inferred that she covers global perspectives within the healthcare & pharmaceutical industry. Therefore, when reaching out to her, it would be most effective to provide international viewpoints and insights along with local ones where applicable.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Laura Joszt, Mary Caffrey
Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.
By: Laura Joszt
CMS is creating infrastructure to improve coverage of prescription digital therapeutics (PDTs), and new legislation would also drive uptake of PDTs.
New legislation would clarify rules around value-based contracts in Medicaid, and a new model is expanding access to gene therapies, explained Adam Colborn, JD, of AMCP.
By: Mary Caffrey, Laura Joszt
Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.
Key Updates in the Management of Small Cell Lung Cancer More News
By: Peter Wehrwein, Laura Joszt
The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.
By: Laura Joszt
The chimeric antigen receptor T-cell therapy obecabtagene autoleucel received approval to treat patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia.
By: Laura Joszt
Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.
By: Laura Joszt
In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for patients with hereditary angioedema.
By: Laura Joszt
A new risk score model for hepatocellular carcinoma using standard clinical data can better identify individuals at risk better than the current standard risk models.
(833) 317-6278 
